Consensus Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
After hours 01:00:00 | |||
| 97.52 USD | -0.20% |
|
96.46 | -1.09% |
| 12-02 | Boston Scientific Insider Sold Shares Worth $1,758,189, According to a Recent SEC Filing | MT |
| 12-02 | Aclarion, Inc. Appoints Jason Brosniak as Commercial Director for the Eastern U.S | CI |
Evolution of the Average Target: Boston Scientific Corporation
Evolution of the Target Price: Boston Scientific Corporation
Changes in Analyst Recommendations: Boston Scientific Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +29.7% | |||||
| +8.24% | |||||
| +3.65% | |||||
| +13% | |||||
| +31.22% | |||||
| +10.49% | |||||
| +16.43% | |||||
| +3.1% | |||||
| +14.39% | |||||
| +38.37% | |||||
| Average | +16.86% | |||||
| Weighted average by Cap. | +14.09% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Daiwa Securities | |
| UBS | |
| Rothschild & Co Redburn | |
| Goldman Sachs | |
| Jefferies & Co. | |
| Baird | |
| Leerink Partners | |
| Morgan Stanley | |
| Wells Fargo Securities | |
| Evercore ISI | |
| Piper Sandler | |
| Barclays | |
| Canaccord Genuity | |
| Truist Securities | |
| BTIG | |
| Oppenheimer | |
| CICC Research | |
| Bernstein | |
| Wolfe Research | |
| Mizuho Securities | |
| Raymond James | |
| Deutsche Bank Securities | |
| RBC Capital Markets | |
| Needham & Co. | |
| Citigroup | |
| Nephron Research | |
| William O'Neil & Co | |
| Argus | |
| Stifel Nicolaus | |
| Redburn Atlantic | |
| JPMorgan Chase | |
| TD Cowen | |
| CL King | |
| BofA Securities | |
| SVB Leerink | |
| Credit Suisse | |
| Atlantic Equities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSX Stock
- Consensus Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition